STAT3 Mediates Resistance to MEK Inhibitor Through MicroRNA MiR-17

Overview

Journal Cancer Res

Specialty Oncology

Date 2011 Mar 30

PMID 21444672

Citations 53

Authors

Bingbing Dai

Jieru Meng

Michael Peyton

Luc Girard

William G Bornmann

Lin Ji

John D Minna

Bingliang Fang

Jack A Roth

Affiliations

Soon will be listed here.

Abstract

AZD6244 is a small molecule inhibitor of the MEK (MAP/ERK kinase) pathway currently in clinical trials. However, the mechanisms mediating intrinsic resistance to MEK inhibition are not fully characterized. To define molecular mechanisms of MEK inhibitor resistance, we analyzed responses of 38 lung cancer cell lines following AZD6244 treatment and their genome-wide gene expression profiles and identified a panel of genes correlated with sensitivity or resistance to AZD6244 treatment. In particular, ingenuity pathway analysis revealed that activation of the STAT3 pathway was associated with MEK inhibitor resistance. Inhibition of this pathway by JSI-124, a STAT3-specific small molecule inhibitor, or with STAT3-specific siRNA sensitized lung cancer cells to AZD6244 and induced apoptosis. Moreover, combining a STAT3 inhibitor with AZD6244 induced expression of BIM and PARP cleavage, whereas activation of the STAT3 pathway inhibited BIM expression and elicited resistance to MEK inhibitors. We found that the STAT3-regulated microRNA miR-17 played a critical role in MEK inhibitor resistance, such that miR-17 inhibition sensitized resistant cells to AZD6244 by inducing BIM and PARP cleavage. Together, these results indicated that STAT3-mediated overexpression of miR-17 blocked BIM expression and caused resistance to AZD6244. Our findings suggest novel approaches to overcome resistance to MEK inhibitors by combining AZD6244 with STAT3 or miR-17 inhibitors.

Citing Articles

Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in - and -mutant cancer cells.

Zhang H, Read A, Cataisson C, Yang H, Lee W, Turk B Sci Signal. 2024; 17(836):eadd5073.

PMID: 38743809 PMC: 11238902. DOI: 10.1126/scisignal.add5073.

Novel Histopathological Biomarkers in Prostate Cancer: Implications and Perspectives.

Kielb P, Kowalczyk K, Gurwin A, Nowak L, Krajewski W, Sosnowski R Biomedicines. 2023; 11(6).

PMID: 37371647 PMC: 10295349. DOI: 10.3390/biomedicines11061552.

MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression.

Farnsworth D, Inoue Y, Johnson F, de Rappard-Yuswack G, Lu D, Shi R NPJ Precis Oncol. 2022; 6(1):88.

PMID: 36418460 PMC: 9684561. DOI: 10.1038/s41698-022-00328-x.

UV-Induced Somatic Mutations Driving Clonal Evolution in Healthy Skin, Nevus, and Cutaneous Melanoma.

Loras A, Gil-Barrachina M, Marques-Torrejon M, Perez-Pastor G, Martinez-Cadenas C Life (Basel). 2022; 12(9).

PMID: 36143375 PMC: 9503451. DOI: 10.3390/life12091339.

KRAS as a Key Oncogene in the Clinical Precision Diagnosis and Treatment of Pancreatic Cancer.

Dai M, Chen S, Teng X, Chen K, Cheng W J Cancer. 2022; 13(11):3209-3220.

PMID: 36118526 PMC: 9475360. DOI: 10.7150/jca.76695.

References

Solit D, Garraway L, Pratilas C, Sawai A, Getz G, Basso A . BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2005; 439(7074):358-62. PMC: 3306236. DOI: 10.1038/nature04304. View

Sheridan C, Brumatti G, Martin S . Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim. J Biol Chem. 2008; 283(32):22128-35. DOI: 10.1074/jbc.M800271200. View

Cragg M, Jansen E, Cook M, Harris C, Strasser A, Scott C . Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest. 2008; 118(11):3651-9. PMC: 2571034. DOI: 10.1172/JCI35437. View

Giese B, Au-Yeung C, Herrmann A, Diefenbach S, Haan C, Kuster A . Long term association of the cytokine receptor gp130 and the Janus kinase Jak1 revealed by FRAP analysis. J Biol Chem. 2003; 278(40):39205-13. DOI: 10.1074/jbc.M303347200. View

Zhang Y, Turkson J, Smithgall T, Levitzki A, Kraker A, Krolewski J . Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J Biol Chem. 2000; 275(32):24935-44. DOI: 10.1074/jbc.M002383200. View

Guo W, Wu S, Liu J, Fang B . Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res. 2008; 68(18):7403-8. PMC: 2678915. DOI: 10.1158/0008-5472.CAN-08-1449. View

Wee S, Jagani Z, Xiang K, Loo A, Dorsch M, Yao Y . PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 2009; 69(10):4286-93. DOI: 10.1158/0008-5472.CAN-08-4765. View

Yang J, Chang C, Xia W, Wang Y, Wong K, Engelman J . Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer. Cancer Res. 2010; 70(11):4709-18. PMC: 2895805. DOI: 10.1158/0008-5472.CAN-09-4524. View

Yang J, Zong C, Xia W, Yamaguchi H, Ding Q, Xie X . ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008; 10(2):138-48. PMC: 2376808. DOI: 10.1038/ncb1676. View

10.

Ewings K, Wiggins C, Cook S . Bim and the pro-survival Bcl-2 proteins: opposites attract, ERK repels. Cell Cycle. 2007; 6(18):2236-40. DOI: 10.4161/cc.6.18.4728. View

11.

Dry J, Pavey S, Pratilas C, Harbron C, Runswick S, Hodgson D . Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res. 2010; 70(6):2264-73. PMC: 3166660. DOI: 10.1158/0008-5472.CAN-09-1577. View

12.

Xiao C, Srinivasan L, Calado D, Patterson H, Zhang B, Wang J . Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol. 2008; 9(4):405-14. PMC: 2533767. DOI: 10.1038/ni1575. View

13.

Brunet A, Bonni A, Zigmond M, Lin M, Juo P, Hu L . Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999; 96(6):857-68. DOI: 10.1016/s0092-8674(00)80595-4. View

14.

Adjei A, Cohen R, Franklin W, Morris C, Wilson D, Molina J . Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008; 26(13):2139-46. PMC: 2718422. DOI: 10.1200/JCO.2007.14.4956. View

15.

Cai D, Shames D, Raso M, Xie Y, Kim Y, Pollack J . Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. Cancer Res. 2010; 70(16):6477-85. PMC: 2922434. DOI: 10.1158/0008-5472.CAN-10-0005. View

16.

Pratilas C, Hanrahan A, Halilovic E, Persaud Y, Soh J, Chitale D . Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res. 2008; 68(22):9375-83. PMC: 2649746. DOI: 10.1158/0008-5472.CAN-08-2223. View

17.

Wang D, Boerner S, Winkler J, LoRusso P . Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta. 2006; 1773(8):1248-55. DOI: 10.1016/j.bbamcr.2006.11.009. View

18.

Ventura A, Young A, Winslow M, Lintault L, Meissner A, Erkeland S . Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell. 2008; 132(5):875-86. PMC: 2323338. DOI: 10.1016/j.cell.2008.02.019. View

19.

Yu H, Pardoll D, Jove R . STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009; 9(11):798-809. PMC: 4856025. DOI: 10.1038/nrc2734. View

20.

Sos M, Fischer S, Ullrich R, Peifer M, Heuckmann J, Koker M . Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A. 2009; 106(43):18351-6. PMC: 2757399. DOI: 10.1073/pnas.0907325106. View